Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect

Altimmune (ALT) is set to report Q2 earnings, with expectations for a $0.32 per share loss and no revenue, as the company lacks a marketed drug. Investor attention will center on updates regarding its lead pipeline candidate, pemvidutide, a GLP-1/glucagon dual agonist. Recent Phase IIb data for pemvidutide in MASH showed strong MASH resolution but failed to demonstrate statistically significant fibrosis improvement, contributing to ALT's 43% year-to-date share decline. Further details are anticipated on the development path for pemvidutide, including newly initiated Phase II studies for alcohol liver disease (ALD) and alcohol use disorder (AUD).

Analysis

Altimmune's upcoming Q2 2025 earnings report is set against a backdrop of significant clinical uncertainty and negative investor sentiment for its lead asset, pemvidutide. The primary overhang stems from the recent top-line data from the Phase IIb IMPACT study in MASH, which yielded mixed results. While the trial successfully met one primary endpoint, demonstrating statistically significant MASH resolution in 52.1% to 59.1% of participants versus 19.1% for placebo, it crucially failed to achieve statistical significance on the co-primary endpoint of fibrosis improvement. This failure on a key endpoint triggered a sharp sell-off, contributing to the stock's 43% year-to-date decline, which starkly contrasts with the industry's 7.2% gain. As a clinical-stage biotech with no marketed products, the company is expected to report a loss of 32 cents per share with no revenue. Investor focus will be entirely on management's forward-looking commentary regarding the development path for pemvidutide, especially its viability in MASH, and any progress updates on the newly initiated Phase II trials for alcohol liver disease (ALD) and alcohol use disorder (AUD), which may signal a strategic pivot.

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings call for management's revised development strategy for pemvidutide in MASH, particularly how they plan to address the failure to meet the statistically significant fibrosis improvement endpoint.
• Given the stock's severe underperformance and the critical data setback, a cautious or neutral stance is warranted until there is greater clarity on a viable regulatory and commercial path forward for pemvidutide.
• Monitor any updates on the new Phase II trials in alcohol-related liver and use disorders, as success in these alternative indications could represent a potential future value driver, but does not mitigate the immediate concerns from the MASH trial results.